RxDoctor Payments Data

Robert Rudd, MD

Internal Medicine · Memphis, TNNPI 1093166647

Payments from drug & device makers

$1,148in general payments, 2019–2025

Across 29 payments — averaging $39.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$400
  • AstraZeneca$214
  • Jazz Pharmaceuticals Inc.$154
  • Axsome Therapeutics, Inc.$146
  • Insmed, Inc.$46
  • 3b Medical, Inc.$36
  • plus $152 from 7 others

What the payments were for

  • Food & beverage$1,11097%
  • Education$383%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,148 in reported general payments places this provider in the 70th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$64,697
Medicare patients
243
Services billed
591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$63,622
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$14,563
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$8,003
Albuterol Sulfate HfaAlbuterol Sulfate151$5,358
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,868
Azelastine Hcl87$2,716
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,550
Ventolin HfaAlbuterol Sulfate18$1,568
Montelukast Sodium34$266
Fluticasone Propionate16$237
Omeprazole17$210
Azithromycin28$94
Prednisone24$76

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$18$78,18596 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →